Guardian Capital Advisors LP cut its holdings in Eli Lilly and Company (NYSE:LLY) by 7.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,415 shares of the company’s stock after selling 360 shares during the period. Guardian Capital Advisors LP’s holdings in Eli Lilly and were worth $371,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of LLY. BlackRock Inc. increased its holdings in shares of Eli Lilly and by 2,628.5% in the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the last quarter. Dodge & Cox increased its holdings in shares of Eli Lilly and by 22,094.9% in the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after buying an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Eli Lilly and by 91.1% in the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after buying an additional 2,714,505 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and by 3.3% in the 1st quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the last quarter. Finally, Winslow Capital Management LLC increased its holdings in shares of Eli Lilly and by 79.7% in the 1st quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after buying an additional 1,719,538 shares during the last quarter. Hedge funds and other institutional investors own 76.61% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $82.89 on Monday. The stock has a market cap of $91,269.77, a PE ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.88 EPS. equities research analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.51%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

A number of analysts have recently weighed in on LLY shares. Leerink Swann downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $93.00 to $90.00 in a report on Wednesday, July 26th. BMO Capital Markets restated an “underperform” rating and issued a $73.00 target price on shares of Eli Lilly and in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price on the stock. in a report on Wednesday, July 26th. UBS AG downgraded shares of Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a report on Wednesday, July 26th. Finally, TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $89.76.

WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/20/guardian-capital-advisors-lp-trims-stake-in-eli-lilly-and-company-lly.html.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 772,003 shares of company stock valued at $64,837,441. 0.20% of the stock is owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.